These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 34773448)

  • 1. C-reactive protein as an effector molecule in Covid-19 pathogenesis.
    Mosquera-Sulbaran JA; Pedreañez A; Carrero Y; Callejas D
    Rev Med Virol; 2021 Nov; 31(6):e2221. PubMed ID: 34773448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
    England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
    Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
    Yang C; Xiao SY
    Biomed Pharmacother; 2021 Mar; 135():111233. PubMed ID: 33433350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
    Azar MM; Shin JJ; Kang I; Landry M
    Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
    Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
    Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
    Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.
    Ahmadian E; Hosseiniyan Khatibi SM; Razi Soofiyani S; Abediazar S; Shoja MM; Ardalan M; Zununi Vahed S
    Rev Med Virol; 2021 May; 31(3):e2176. PubMed ID: 33022818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune dysregulation and system pathology in COVID-19.
    Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q
    Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
    Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
    Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P
    Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
    Egilmezer E; Rawlinson WD
    Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
    Asrani P; Hassan MI
    Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge.
    Buszko M; Park JH; Verthelyi D; Sen R; Young HA; Rosenberg AS
    Nat Immunol; 2020 Oct; 21(10):1146-1151. PubMed ID: 32855555
    [No Abstract]   [Full Text] [Related]  

  • 19. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
    Chrousos GP; Meduri GU
    Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
    [No Abstract]   [Full Text] [Related]  

  • 20. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.